Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Doctors are sending out a warning after children as young as 10 years old are using drugs like Ozempic and Wegovy.

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.